AB3279
Anti-Hexokinase Type II Antibody
Chemicon®, from rabbit
別名:
HK II
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ELISA, ICC, WB
Species reactivity:
rat, human
Citations:
15
Technique(s):
ELISA: suitable, immunocytochemistry: suitable, western blot: suitable
Uniprot accession no.:
biological source
rabbit
conjugate
unconjugated
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
rat, human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable, immunocytochemistry: suitable, western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... HK2(3099)
Analysis Note
Control
insulin-responsive tissues such as skeletal muscle
insulin-responsive tissues such as skeletal muscle
Application
Anti-Hexokinase Type II Antibody is an antibody against Hexokinase Type II for use in ELISA, IC & WB.
Research Category
Metabolism
Metabolism
Research Sub Category
Enzymes & Biochemistry
Enzymes & Biochemistry
Western Blot: 1:5,000-1:10,000.
Immunocytochemistry using indirect immunofluorescence.
ELISA
Optimal working dilutions must be determined by the end user.
Immunocytochemistry using indirect immunofluorescence.
ELISA
Optimal working dilutions must be determined by the end user.
Biochem/physiol Actions
Reacts with the Type II isozyme of rat hexokinase (102 kDa). No reactivity with the Type I or Type III isozymes of rat hexokinase by immunoblot or ELISA. Reactivity with human and hamster Type II isozyme has been confirmed by immunoblotting, and reactivity with Type II isozyme from other mammalian species is expected.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
102 kDa
Immunogen
Recombinant rat Type II hexokinase.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Physical form
Format: Purified
Immunodepleted Serum
Liquid. Partially Purified rabbit Serum. Antibodies reactive with the Type I isozyme were present in the original antiSerum; these were removed by affinity chromatography on a column of immobilized Type I isozyme, and the affinity-depleted Serum restored to original volume.
Preparation Note
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
10 - Combustible liquids
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Enzymatic properties of the N- and C-terminal halves of human hexokinase II.
Keun Jae Ahn,Jongsun Kim,Mijin Yun,Jeon Han Park,Jong Doo Lee
Bmb Reports null
Yuya Nogami et al.
BMC medical imaging, 16, 31-31 (2016-04-27)
We report two cases of anisakiasis lesions that were initially suspected to be recurrence of gynecological cancer by positron emission tomography-computed tomography (PET-CT). Both cases were extragastrointestinal anisakiasis that is very rare. The first case was a patient with endometrial
Heidi Lyng et al.
BMC genomics, 7, 268-268 (2006-10-24)
A better understanding of the development of metastatic disease and the identification of molecular markers for cancer spread would be useful for the design of improved treatment strategies. This study was conducted to identify gene expressions associated with metastatic phenotypes
Chung-Ling Lu et al.
PloS one, 10(3), e0121046-e0121046 (2015-03-26)
A unique feature of cancer cells is to convert glucose into lactate to produce cellular energy, even under the presence of oxygen. Called aerobic glycolysis [The Warburg Effect] it has been extensively studied and the concept of aerobic glycolysis in
Wenshan Hao et al.
The Journal of biological chemistry, 285(17), 12647-12654 (2010-01-30)
Cancer cells constantly adapt to oxidative phosphorylation (OXPHOS) suppression resulting from hypoxia or mitochondria defects. Under the OXPHOS suppression, AMP-activated protein kinase (AMPK) regulates global metabolism adjustments, but its activation has been found to be transient. Whether cells can maintain
グローバルトレードアイテム番号
| カタログ番号 | GTIN |
|---|---|
| AB3279 | 04053252589539 |
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）